Vaccines: Moderna to join S&P 500

Called the Tesla of biotech by some analysts, Moderna will join the

S&P 500 after its valuation surpassed $100 billion last week, said Cristin Flanagan and Bailey Lipschultz in Bloomberg.com. The Covid-19 vaccine maker’s shares have “skyrocketed more than threefold over the past 12 months.” Moderna is entering the S&P index after reporting only one quarter of profitability in its two and a half years as a public company. Moderna is now using its messenger-RNA technology to “target new vaccines and drugs for other viruses like Zika and the flu.”